February 12, 1997

More on Screening for Mild Thyroid Failure-Reply

Author Affiliations

Johns Hopkins University Baltimore, Md

JAMA. 1997;277(6):459. doi:10.1001/jama.1997.03540300027022

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.  —Dr Helfand points out that it is not possible to know in advance which symptomatic patients with mild thyroid failure will respond to thyroxine sodium therapy. He questions the precise benefit achieved from symptom relief in our decision and cost-effectiveness analysis and the impact that uncertainty regarding the reversibility of symptoms has on the final results.We have considered this issue further and find that it has little effect on the results of the model for 3 reasons. First, relatively few patients were treated for potentially reversible symptoms alone. Because there are no data regarding overlap of the 3 treatment indications—reversible symptoms (28% of patients), antithyroid antibodies predicting progression of disease (67% of women, 40% of men), and hypercholesterolemia (25% of patients)—we assumed that these treatment indications were independently associated in patients with mild thyroid failure. Consequently, most patients with symptoms also had another indication for treatment; only 6% of